Alps Advisors Inc Morphic Holding, Inc. Transaction History

Alps Advisors Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$26.12 - $34.07 $98,263 - $128,171	3,762 Added 10.66%	39,054 $1.33 Million
Q1 2024 May 14, 2024	BUY	$26.64 - $40.31 $48,511 - $73,404	1,821 Added 5.44%	35,292 $1.24 Million
Q4 2023 Feb 14, 2024	SELL	$19.95 - $31.0 $37,366 - $58,063	-1,873 Reduced 5.3%	33,471 $966,000
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $48,739 - $135,774	2,285 Added 6.91%	35,344 $809,000
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $1.13 Million - $2.05 Million	33,059 New	33,059 $1.9 Million

4.71M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.